Advertisement
 
Research Topics
Subscribe to Research Topics
View Sample

FREE Email Newsletter

Daily news and top headlines for drug research professionals

PDF Providing Grants to Speed New Parkinson's Treatments

March 28, 2014 3:05 pm | News | Comments

The Parkinson's Disease Foundation (PDF) is pleased to announce $20,000 in grant funding to support patient-centered research at four leading Parkinson's disease research institutions. Read more...                

Women with BRCA1 Mutation Could Use Drugs to Cut Cancer Risk

March 28, 2014 2:46 pm | News | Comments

Cancer researchers have discovered that women affected with BRCA1 mutation could use drugs, which are already available, to reduce their risk of developing the disease, rather than undergo irreversible surgery. Read more...       

Idera Posts Positive Data in Phase 2 Psoriasis Trial

March 28, 2014 2:27 pm | News | Comments

Idera Pharmaceuticals Inc. announced positive top-line data from its randomized, double-blind, placebo-controlled Phase 2 trial of IMO-8400 in 32 patients with moderate-to-severe plaque psoriasis. Read more...            

Advertisement

Oramed's Oral Insulin Trial Hits Phase 2a

March 28, 2014 10:50 am | News | Comments

Oramed Pharmaceuticals Inc. announced that the first patient has been enrolled in its U.S. Phase 2a trial for its orally ingestible insulin capsule, ORMD-0801, in the treatment of type 1 diabetes (T1DM).  Read more...         

Pfizer Cholesterol Drug Hits Main Trial Goal

March 27, 2014 3:22 pm | News | Comments

Pfizer Inc. announced the Phase 2b results of a study of investigational bococizumab, the proposed generic name for RN316. The study met its primary endpoint across all doses, showing that bococizumab significantly reduced low density lipoprotein cholesterol (LDL-C). Read more...

Baxter Split Spawns New Biopharmaceutical Company

March 27, 2014 2:59 pm | by Linda A. Johnson, AP Business Writer | News | Comments

Following a rival's lead, Baxter International Inc. said it's planning a breakup into two health care companies, a biopharmaceutical company and a medical products business, as it tries to boost innovation and profitability and reward shareholders. Read more...

Drug Companies to Phase Out Animal Antibiotics

March 27, 2014 2:53 pm | by Mary Clare Jalonick | News | Comments

Twenty-five pharmaceutical companies are voluntarily phasing out the use of antibiotics for growth promotion in animals processed for meat, the Food and Drug Administration said Wednesday. Read more...              

Tampering Forces Massive Alli Recall

March 27, 2014 11:04 am | News | Comments

GlaxoSmithKline Consumer Healthcare is voluntarily recalling all Alli weight loss products from U.S. and Puerto Rico retailers as the company believes that some packages of the product were tampered with and may contain product that is not authentic Alli. Read more...

Advertisement

Novartis Treatment Promising Against Drug-Resistant Lung Cancer

March 27, 2014 10:48 am | News | Comments

Novartis published clinical trial results showing the investigational compound LDK378 (ceritinib) achieved an overall response rate of 58% and a median progression-free survival of seven months in adults with advanced anaplastic lymphoma kinase positive non-small cell lung cancer. Read more...

Germany's Merck Launches Phase 3 Fertility Study

March 27, 2014 10:35 am | News | Comments

Merck announced the enrollment of the first patient into a new Phase 3 study in the area of fertility, marking another step in its efforts to explore innovative solutions in areas of unmet medical need.  Read more...          

New Cancer Drug Targets CEA Protein

March 27, 2014 10:17 am | News | Comments

A new cancer drug, based on further development of a discovery originally made by Cancer Research UK, has entered a clinical trial to target a wide range of cancers. Read more...                      

Stimulant Drugs Can Impair Neuronal Activity

March 26, 2014 2:38 pm | News | Comments

Researchers have discovered impaired neuronal activity in the parts of the brain associated with anticipatory functioning among occasional 18- to 24-year-old users of stimulant drugs. Read more...                

Pfizer's Genotropin Hits Phase 3b Endpoints

March 26, 2014 2:09 pm | News | Comments

Pfizer Inc. announced the top-line results from a Phase 3b study evaluating the 24-month efficacy of Genotropin (somatropin) on the height in small-for-gestational-age (SGA) children 24 to 30 months old. Read more...           

Advertisement

Under Fire, Zohydro Maker Touts Safety Board

March 26, 2014 1:54 pm | by Matthew Perrone, AP Health Writer | News | Comments

After months of criticism over its recently launched painkiller Zohydro, the maker of the powerful narcotic is highlighting an unusual oversight board that it's assembled to try and prevent abuse of the drug. Read more...             

SwRI Wins $8.3M HHS Grant for Cyanide Antidote Development

March 26, 2014 1:38 pm | News | Comments

The U.S. Department of Health and Human Services Biomedical Advanced Research and Development Authority has awarded Southwest Research Institute an $8.3 million contract extension to continue development of a nasal-delivery, first-line treatment system to combat cyanide poisoning. Read more...

Drugs for Terminally Ill Clear New Hurdle

March 26, 2014 1:05 pm | News | Comments

A proposal to allow terminally ill people access to drugs that are still completing clinical trials cleared its first test in the Colorado Legislature on Tuesday. Read more...                      

Pharmacists Urged to Withhold Compounded Execution Drugs

March 26, 2014 12:56 pm | by Andrew Welsh-Huggins, AP Legal Affairs Writer | News | Comments

Several human rights and anti-death penalty groups have asked the American Pharmacists Association to prohibit members from participating in executions, a request that comes as states increasingly turn to pharmacists for lethal injection drugs. Read more...

Gold-Based Drug Shows Promise Against Bone Cancer

March 26, 2014 12:35 pm | News | Comments

A gold-based drug currently used in human and veterinary medicine to manage certain immune diseases may prove useful in combating osteosarcoma, researchers report. Read more...                      

Immunotherapy Data Heralds New Era of Lung Cancer Treatment

March 26, 2014 12:26 pm | News | Comments

For decades, scientists and doctors thought immunotherapy– treatments that harness the immune system to fight a disease– was of marginal benefit in lung cancer. Now, a new class of drugs known as “immunocheckpoint regulators” have shown huge potential in treating the disease. Read more...

AM-Pharma Announces Phase 1 AKI Drug Data

March 26, 2014 12:15 pm | News | Comments

AM-Pharma B.V. announced the results of its Phase 1 trial with of recAP (recombinant human Alkaline Phosphatase), showing that both single and multiple ascending doses are safe and well tolerated. Read more...          

Inovio Snags Best Therapeutic Award at World Vaccine Congress

March 26, 2014 10:05 am | News | Comments

Inovio Pharmaceuticals Inc. announced that it was recognized with three industry awards at the World Vaccine Congress, being held this week in Washington, D.C. Read more...                       

Astellas Wins Prostate Cancer Approval for Xtandi in Japan

March 25, 2014 2:15 pm | News | Comments

Astellas Pharma announced that Astellas has obtained marketing approval of their oral androgen receptor signaling inhibitor, Xtandi capsules 40mg (enzalutamide) for the treatment of patients with castration-resistant prostate cancer in Japan. Read more...

Spark, Genable Technologies Collaboration on Rare Gene Therapy

March 25, 2014 2:04 pm | News | Comments

Spark Therapeutics and Genable Technologies announced that they have entered into a collaboration agreement for Genable's lead therapeutic to treat rhodopsin-linked autosomal dominant retinitis pigmentosa (RHO adRP), GT038. Read more...    

New Cancer Drug Manipulates Signaling, Energy Systems

March 25, 2014 1:59 pm | News | Comments

Researchers have developed a new drug that can manipulate the body’s natural signaling and energy systems, allowing the body to attack and shut down cancerous cells. Read more...                     

Study Questions First-Line Treatment for Advanced Sarcoma

March 25, 2014 1:50 pm | News | Comments

A new study does not support administration of intensified doxorubicin and ifosfamide for palliation of advanced soft tissue sarcoma, unless the objective is to shrink the tumor. Read more...                 

X
You may login with either your assigned username or your e-mail address.
The password field is case sensitive.
Loading